New double-drug therapy gives fresh hope to Brits with oesophagus cancer

New trial results suggest that patients given the immunotherapy medicine tislelizumab alongside chemotherapy are likely to live much longer than those given chemotherapy alone.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news